State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Tilray Brands Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B), while Tilray Brands Inc trades at $3.53 (market cap $530.54M). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is far larger — about 8.2× Tilray Brands Inc's market cap, and Tilray Brands Inc is more actively traded (9,099,075 versus 3,211,044). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days and Tilray Brands Inc for 31 Days on average.
| SJNK | TLRY | |
|---|---|---|
Market Cap | $4.35B | $530.54M |
Volume | 3,211,044 | 9,099,075 |
Sector | Fixed Income | Health |
52-Week High | $25.57 | $21.00 |
52-Week Low | $24.13 | $3.57 |
Typical Hold Time | 41 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.20, down 0.21% with a bearish technical outlook. The ETF shows strong institutional interest despite recent selling activity by some firms. Dividend distributions remain consistent with recent payments of $0.14-$0.15 per share, providing income appeal in a rising rate environment.
The ETF faces headwinds from technical weakness but maintains income appeal through consistent dividends. Key risks include interest rate sensitivity and institutional selling pressure, while the current yield advantage over Treasuries presents opportunity for income-focused investors in the high-yield bond space.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →